Company news
Q32 Bio Inc. (NASDAQ:QTTB) news
Every Q32 Bio Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer
September 14, 2026
Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 5, 2026
Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants
July 14, 2026
Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
July 13, 2026
Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata
July 13, 2026
Q32 Bio to Report 36-Week Topline Results from Part B of SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata on July 13, 2026
July 10, 2026
Q32 Bio Announces $55 Million Private Placement Financing
May 27, 2026
Q32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 5, 2026
Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference
April 8, 2026
Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
March 10, 2026
Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 18, 2026
Q32 Bio Announces $10.5 Million Registered Direct Offering
February 17, 2026
Q32 Bio Sells Complement Inhibitor ADX-097
December 1, 2025
Akebia Announces Establishment of Rare Kidney Disease Pipeline
December 1, 2025
Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 13, 2025
Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata
October 21, 2025
Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference
August 28, 2025
Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 6, 2025
Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer
June 25, 2025
OXB completes acquisition of remaining stake in US subsidiary
June 23, 2025
Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 8, 2025
Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata
April 30, 2025
Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopeci...
April 16, 2025
Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update
March 11, 2025
Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 America...
March 8, 2025
Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 202...
February 28, 2025
Q32 Bio to Participate in Upcoming March Investor Conferences
February 26, 2025
Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata
February 10, 2025
Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference
February 4, 2025
Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program
December 10, 2024
Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 7, 2024
Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference
November 5, 2024
Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephro...
October 14, 2024
Q32 Bio to Participate in Upcoming September Investor Conferences
August 29, 2024
Q32 Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 8, 2024
Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis
July 9, 2024
Q32 Bio Joins Russell 3000® Index
July 1, 2024
Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 9, 2024
Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer
April 3, 2024
Homology Medicines Declares Distribution to Common Stockholders
March 18, 2024
Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency
January 3, 2024
Q32 Bio and Homology Medicines Announce Merger Agreement
November 16, 2023
Homology Medicines Reports Third Quarter 2023 Financial Results
November 14, 2023
Homology Medicines Reports Second Quarter 2023 Financial Results and Recent Highlights
August 14, 2023
Homology Medicines Announces Encouraging Initial Data from First Dose Level in the pheEDIT Trial Evaluating Gene Editing Candidate HMI-10...
July 27, 2023
Homology Medicines Announces Plan to Evaluate Strategic Options for the Company and its Genetic Medicines Programs, including HMI-103 Gen...
July 27, 2023
Homology Medicines Announces First Data from IND-Enabling Studies with GTx-mAb Candidate HMI-104 for PNH, Which Demonstrated Sustained Ex...
May 16, 2023
Homology Medicines Reports First Quarter 2023 Financial Results and Recent Highlights
May 11, 2023
Homology Medicines Announces Upcoming Presentations Highlighting its Genetic Medicines Platform, including New Data from IND-Enabling Stu...
May 3, 2023
Homology Medicines Announces Presentations on Design of Ongoing Gene Editing and Gene Therapy Trials for PKU and Hunter Syndrome at ACMG ...
March 15, 2023